Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (MET52)

Brief description of study

The primary objective of the study is to demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, W, and Y in terms of hSBA vaccine seroprotection (antibody titer ≥ 1:8) when MenACYW conjugate vaccine is administered concomitantly with Bexsero® in the second year of life compared to when MenACYW conjugate vaccine is given alone The secondary objective is to compare the hSBA antibody response in terms of geometric mean titers (GMTs) against meningococcal serogroups A, C, W, and Y when MenACYW conjugate vaccine is administered concomitantly with Bexsero® or when MenACYW conjugate vaccine is given alone in the second year of life; to describe the hSBA and rSBA antibody responses against meningococcal serogroups A, C, W, and Y before and after the 1st dose of MenACYW conjugate vaccine administered at 3 months of age, before and after the 2nd dose of MenACYW conjugate vaccine administered at 12 to 13 months of age for Group 1 and Group 2; to describe the hSBA and rSBA antibody persistence against meningococcal serogroups A, C, W, and Y after the 1st dose of MenACYW conjugate vaccine administered at 3 months of age for Group 1 and Group 2

Study duration per participant will be approximately 11 to 12 months

Clinical Study Identifier: NCT03632720

You may be eligible for this study if you meet the following criteria:

  • Conditions: Healthy Volunteers (Meningococcal Infection)
  • Age: Between 56 Days - 89 Days
  • Gender: Male or Female

Inclusion Criteria:

  • Aged ≥ 56 to ≤ 89 days on the day of the first study visit
  • Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg (or 5 lb and 8 oz)
  • Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations)
  • Participant and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures

Exclusion Criteria:

        -- Participation at the time of study enrollment (or in the 4 weeks preceding the first
        trial vaccination) or planned participation during the present trial period in another
        clinical trial investigating a vaccine, drug, medical device, or medical procedure
          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination (at Visit
             1) or planned receipt of any vaccine in the 4 weeks before and/or following any trial
             vaccination except for influenza vaccination, which may be received at a gap of at
             least 2 weeks before or 2 weeks after any study vaccines. This exception includes
             monovalent pandemic influenza vaccines and multivalent influenza vaccines
          -  Previous vaccination against meningococcal disease with either the trial vaccine or
             another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal
             vaccine containing serogroups A, C, W, or Y; or meningococcal B serogroup-containing
             vaccine)
          -  Previous vaccination (before Visit 1) with any pneumococcal, diphtheria, tetanus,
             pertussis, hepatitis B, Haemophilus influenzae type b (Hib), poliovirus, and/or
             rotavirus vaccines. Receipt of BCG vaccine at birth is acceptable
          -  Receipt of immune globulins, blood or blood-derived since birth
          -  Known or suspected congenital or acquired immunodeficiency, including Severe Combined
             Immunodeficiency disorder (SCID); or receipt of immunosuppressive therapy, such as
             anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid
             therapy (prednisone or equivalent for more than 2 consecutive weeks) since birth
          -  History of any neurologic disorders, including any seizures and progressive neurologic
             disorders or encephalopathy
          -  History of Neisseria meningitidis infection, confirmed either clinically,
             serologically, or microbiologically
          -  History of diphtheria, tetanus, pertussis, poliomyelitis, Hib, hepatitis B,
             Streptococcus pneumoniae, and/or rotavirus infection or disease
          -  At high risk for meningococcal infection during the trial (specifically, but not
             limited to, subjects with persistent complement deficiency, with anatomic or
             functional asplenia, or subjects travelling to countries with high endemic or epidemic
             disease)
          -  History of Guillain-Barré syndrome
          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccines used in the trial or to a vaccine containing
             any of the same substances including neomycin, kanamycin, polymyxin, formaldehyde, and
             latex
          -  Hereditary problems of fructose intolerance, glucose-galactose malabsorption or
             sucrase-isomaltase insufficiency
          -  History of intussusception or uncorrected congenital malformation of the
             gastrointestinal tract that would predispose to intussusception
          -  Verbal report of thrombocytopenia, contraindicating intramuscular vaccination in the
             investigator's opinion
          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding
             inclusion,contraindicating intramuscular vaccination
          -  Chronic illness that, in the opinion of the investigator, is at a stage where it might
             interfere with trial conduct or completion
          -  Any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives, including planning to leave the area of the study
             site before the end of the study
          -  Moderate or severe acute illness/infection (according to investigator judgment), or
             febrile illness (temperature ≥ 38.0°C), or diarrhea or vomiting on the day of
             vaccination. A prospective subject should not be included in the study until the
             condition has resolved or the febrile event has subsided.
          -  Identified as a natural or adopted child of the Investigator or employee with direct
             involvement in the proposed study.

Last updated on 06 Jul 2022

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250